A first-in-class, once-weekly infusion Factor VIII replacement therapy with higher-for-longer levels in the near normal to normal range (over 40%) for most of the week

On February 23rd, 2023, the Food and Drug Administration approved Fc-VWF-XTEN fusion protein-ehtl injection for adults and children with Hemophilia A for: (1) Routine prophylaxis to reduce the frequency of bleeding episodes; (2) On-demand treatment and control of bleeding episodes; and (3) Perioperative management of bleeding.